Moderna Inc (NASDAQ:MRNA) shares are trading higher by 8.5% to $214.34 on continued upward momentum after the company and Merck announced mRNA-4157/V940 in combination with KEYTRUDA, met the primary efficacy endpoint in the Phase 2b KEYNOTE-942 trial.
The results showed that mRNA cancer vaccine + Keytruda demonstrated a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) versus Keytruda alone for the adjuvant treatment of stage III/IV melanoma following complete resection…Read More
See Also: Moderna Soars On Cancer Vaccine News: Here’s What To Watch Going Forward
According to data from Benzinga Pro, MRNA has a 52-week high of $321.30 and a 52-week low of $115.03.
